Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature

Arnold F. Jacobson, Mark I. Travin

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Background: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. Methods: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. Results: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). Conclusions: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.

Original languageEnglish (US)
Pages (from-to)980-993
Number of pages14
JournalJournal of Nuclear Cardiology
Volume22
Issue number5
DOIs
StatePublished - May 15 2015

Fingerprint

Labetalol
Tricyclic Antidepressive Agents
Sympathomimetics
Amiodarone
Reserpine
Calcium Channel Blockers
Drug Interactions
Serotonin and Noradrenaline Reuptake Inhibitors
Clinical Studies

Keywords

  • mIBG
  • myocardial scintigraphy
  • norepinephrine

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Radiology Nuclear Medicine and imaging

Cite this

Impact of medications on mIBG uptake, with specific attention to the heart : Comprehensive review of the literature. / Jacobson, Arnold F.; Travin, Mark I.

In: Journal of Nuclear Cardiology, Vol. 22, No. 5, 15.05.2015, p. 980-993.

Research output: Contribution to journalArticle

@article{24fc5096368047c9855a1fdaae7a057a,
title = "Impact of medications on mIBG uptake, with specific attention to the heart: Comprehensive review of the literature",
abstract = "Background: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. Methods: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. Results: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). Conclusions: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.",
keywords = "mIBG, myocardial scintigraphy, norepinephrine",
author = "Jacobson, {Arnold F.} and Travin, {Mark I.}",
year = "2015",
month = "5",
day = "15",
doi = "10.1007/s12350-015-0170-z",
language = "English (US)",
volume = "22",
pages = "980--993",
journal = "Journal of Nuclear Cardiology",
issn = "1071-3581",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - Impact of medications on mIBG uptake, with specific attention to the heart

T2 - Comprehensive review of the literature

AU - Jacobson, Arnold F.

AU - Travin, Mark I.

PY - 2015/5/15

Y1 - 2015/5/15

N2 - Background: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. Methods: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. Results: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). Conclusions: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.

AB - Background: A critical review of the literature on drug interactions with mIBG uptake was performed to allow formulation of contemporary guidance regarding withholding medications prior to clinical imaging studies. Methods: Published information was extracted on the experimental system used, the quantitative characteristics of the measurements, and whether any data directly examining cardiac tissues were included. Level of evidence for each medication category was assessed on a qualitative scale of very low, low, medium, or high. Strength of medication effect for inhibition of mIBG uptake was judged as none, weak, moderate, or strong. Results: The only medications for which level of evidence was judged high were labetalol and reserpine. Level of evidence was judged medium for tricyclic antidepressants, calcium channel blockers, and antiarrhythmics (specifically amiodarone). Evidence was judged sufficient to recommend withholding labetalol and the tricyclic antidepressants prior to mIBG cardiac imaging. Mechanistic evidence was sufficient to suggest consideration of withdrawal of sympathomimetic amines and serotonin-norepinephrine reuptake inhibitors (SNRIs). Conclusions: As there is strong evidence for inhibition of mIBG uptake in only a small number of compounds, clinical decisions regarding withdrawal of concomitant medications should be individualized by considering the potential consequences of a false-positive (artificially low cardiac uptake) imaging result.

KW - mIBG

KW - myocardial scintigraphy

KW - norepinephrine

UR - http://www.scopus.com/inward/record.url?scp=84942292725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942292725&partnerID=8YFLogxK

U2 - 10.1007/s12350-015-0170-z

DO - 10.1007/s12350-015-0170-z

M3 - Article

C2 - 25975946

AN - SCOPUS:84942292725

VL - 22

SP - 980

EP - 993

JO - Journal of Nuclear Cardiology

JF - Journal of Nuclear Cardiology

SN - 1071-3581

IS - 5

ER -